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DIAGNOSIS OF CYTOMEGALOVIRUS INFECTIONS BY QUALITATIVE AND QUANTITATIVE PCR
IN HIV INFECTED PATIENTS
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SUMMARY
A high incidence of cytomegalovirus (CMV) infections is observed in Brazil. These viruses are causatives of significant morbidity
and mortality among patients with advanced human immunodeficiency virus (HIV) infection. This work, shows the application of a
PCR on determination of CMV load in the buffy coat and plasma. We analyzed the samples of 247 HIV infected patients in order to
diagnose CMV infection and disease. We developed a semi-quantitative PCR that amplifies part of the glycoprotein B (gB) gene of
CMV. The semi-quantitative PCR was carried out only in positive clinical samples in a qualitative PCR confirmed by a nested-PCR.
CD4 lymphocyte count, HIV viral load and CMV disease symptom were correlated with CMV load. CMV genome was detected in
the buffy coat of 82 of 237 (34.6%) patients, in 10 of these the CMV load was determined varying between 928 and 332 880 viral
copies/g DNA. None of these 237 patients developed any suggestive manifestation of CMV disease. For the other 10 HIV infected
patients selected based on the suspicion of CMV disease, CMV genome was detected in only one case. This patient presented a high
CMV load, 8 000 000 copies/g DNA, and developed a disseminated form of CMV disease including hepatitis and retinitis. Our
results were greatly influenced by the impact of the highly active antiretroviral therapy that reduced incidence of CMV viremia and
occurrence of CMV disease in the HIV infected patients.
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INTRODUCTION
Cytomegalovirus (CMV) is a genus of viruses belonging to the
Herpesviridae family. These viruses have sizes that range from 150 to
200 nm, possess an envelop, a matrix and a nucleocapsid containing a
double strand 240 kilobases DNA that codifies 35 structural proteins.
The viral envelop contains at least 8 glycoproteins including the
glycoprotein B, considered as a viral receptor and an important viral
immunoresponse inducer3. As other viruses of this family, CMV is able
of establishing host latency after a period of acute infection16. The exact
sites that allow latent infection are unclear, but polymorphonuclear cells,
dentritic cells, endothelial vascular tissue and salivary glands may contain
the virus11,12.
CMV infections are ubiquitous in Brazil and about 95% of the adult
individuals are CMV seropositives18. After CMV infection in
immunocompetent individuals, a disease occurs in a small number of
cases and it is usually manifested as an infectious mononucleosis-like
syndrome. It is different from what happens with immunodeficient
patients where different clinical manifestations are associated to CMV
disease, such as retinitis, colitis and encephalitis. These clinical
manifestations occurred in 25-40% of AIDS patients before the appearing
of the highly active anti-retroviral therapy (HAART)8,13. In these patients
the disease frequently occurred as a reactivation of latent virus in CMV
seropositive patients. Likewise it has been shown that CD4 lymphocyte
levels below 50 cells/mm3 are important markers in the prognostic of
clinical manifestations of CMV and as well as indicate a disease phase
frequently defined as advanced AIDS5,9.
The diagnosis of CMV infections is commonly done from blood,
urine, bronchoalveolar lavage, and biopsy tissues by virus isolation in
human fibroblast cell culture, detection of virus antigens in blood
leukocytes by enzyme immunoassays, detection of anti-CMV antibodies
by ELISA and by histopathology detecting cells containing inclusion
bodies2.
 Presently, highly sensitive methods such as PCR are used in order
to detect CMV in HIV infected patients. However, due to the high
infection prevalence, it is difficult to interpret results of sensitive PCR
tests for CMV genome detection in clinical samples because a positive
result does not always mean that the virus is the effective etiological
agent. In HIV infected patients the diagnosis of active infection is based
on the detection of the CMV replication in the blood, it is related to high
viremias as well as to a great risk to develop CMV disease. High CMV
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loads in the blood are important predictive factors for active infection
and for the appearing of disease in HIV infected patients15. Thus
quantitative PCR method for determination of CMV loads could be
important tool for diagnosis of active infection and disease, as well as
for CMV disease prediction in AIDS patients. In the present work we
show the application of a qualitative and a quantitative PCR methods on
the diagnosis of CMV infections in HIV infected patients.
MATERIAL AND METHODS
Patients: Two hundred forty seven HIV infected patients managed
at the Division of Infectious Disease of the General Hospital of the School
of Medicine of Ribeirão Preto, São Paulo University were included in
this study. The patients, in distinct stages of infection (Centers for Disease
Control and Prevention, 1993), were those studied between February
1999 to December 2000. The patients were admitted after consenting
agreement. Clinical and laboratory data were obtained from the patients
records, as well as use of highly active anti-retroviral therapy (HAART).
The patients were separated in 2 groups: 237 patients randomly selected
and 10 patients presenting clinical manifestations suggestive of CMV
disease. None of the 247 patients received CMV prophylaxis or CMV
antiviral treatment previously to the beginning of the study.
 This research project was approved by the Ethic Board of the General
Hospital of the School of Medicine of Ribeirão Preto, University of São
Paulo (Process 826/99).
 An association between disease and CMV load was searched in the
participating patients. Clinical manifestations such as retinitis (retin
exsudate, perivascular hemorrhage), gastrointestinal involvement (colitis
and esofagitis confirmed with histological findings or detection of CMV
DNA in situ), and encephalitis (diagnosed based on the detection of
CMV DNA by PCR of samples from cerebro spinal fluid) were associated
to CMV disease8.
DNA purification: Five ml of whole blood samples were collected
in EDTA containing tubes. Peripheral blood leukocytes (PBL) were
separated from the blood samples by centrifugation in a dextran solution
(Sigma, Germany). The pellet containing the PBLs was suspended in
200 µl PBS and the DNA was extracted using the QIAamp DNA Blood
Kit (Qiagen, Germany), according to the manufacturer recommendations.
CMV DNA was also obtained from the supernatant of fibroblast cell
cultures infected with CMV AD169 strain using the QIAamp DNA Blood
Kit (Qiagen, Germany).
Qualitative PCR and nested-PCR for CMV: The reaction mixture of
the qualitative PCR contained in a total volume of 50 µl, 75 mM of Tris-
HCl (pH 9), 2 mM of MgCl2, 50 mM of KCl, 20 mM of (NH4)2SO4,
50 µM of each one of the deoxynucleoside triphosphates, 0.3 µM of primers
gB1 and gB26, and 1 µg of DNA obtained from PBLs. The reaction mixture
was first incubated at 94 °C for 3 min, the temperature was then reduced
to 80 °C, and 2 U of Taq DNA polymerase were added. The PCR mixture
was subjected to 15 cycles of 60 sec at 94 °C, 120 sec at 65 °C, and 120
sec at 72 °C, and to 30 cycles of 60 sec at 94 °C, 90 sec at 55 °C, 120 sec
at 72 °C, and finally to 3 min at 72 °C. Two microliters of this reaction
were used in a nested-PCR containing the same components as mentioned
above, except for the internal primers gBn1 and gBn21. The reaction mixture
was first incubated at 94 oC for 3 min, the temperature was then reduced to
80 °C, and 1 U of Taq DNA polymerase was added. The PCR mixture was
subjected to 30 cycles of 60 sec at 94 °C, 60 sec at 55 °C, and 60 sec at
72 °C, and finally to 3 min at 72 °C. PCR and nested-PCR products were
subjected to electrophoresis in 2% agarose gel and the amplicons bands
were visualized by UV after ethidium bromide staining.
Each PCR assay included a positive control with CMV AD169 DNA
and a negative control containing distilled water. PCR for -globin gene
detection was performed in order to confirm the DNA extracts integrity.
Primer nucleotide sequences are shown in Table 1.
Cloning a fragment of the gB gene of CMV into a pCR II plasmid:
The amplicon of 296 bp obtained from the CMV AD169 DNA in the
PCR using gB1 and gB2 primers was ligated into the plasmid vector
pCR II (Invitrogen, USA). The plasmids were amplified in bacteria (E.
coli) and purified with the Plasmid Míni Kit (Qiagen, Germany). The
plasmids were sequenced with the Thermo Sequenase CY5.5 terminator
kit (Amershan, England), using the M13/Forward-Reverse primers. The
sequencing reaction was resolved in an automated sequencer (Seq 4 x 4,
Pharmacia, USA). The obtained sequence was compared with that of
the CMV AD169 strain (Genbank, sequence M60931) using the DNAsis
software (Hitachi, Japan).
Plasmid quantification: The molecular weight of the plasmid
1204830 added to the insert of 296 bp molecular weight was calculated
considering as 660 the average molecular weight of a base pair and was
found to be 1400190. Therefore 1400190 g of the plasmid contain 6.02
x 1023 plasmid molecules (Avogrado’s number). Thus, the number of
plasmid particles in our stock solution was determined based on the
plasmid DNA concentration obtained by spectrophotometric
measurement at 260 nm. Aliquots of the quantified plasmid were stored
at – 20 °C until use for the CMV semi-quantitative PCR tests.
Sensitivity of the CMV semi-quantitative PCR: The sensitivity of
the CMV semi-quantitative PCR using primers gB1 and gB2 was
determined by testing in quadruplicate decimal dilutions of the cloned
plasmid solution. Amplicons were detected until the 10-8 dilution which
corresponds to 800 plasmids.
CMV semiquantitative PCR: CMV load was determined in all the
clinical samples with positive result in the qualitative PCR. The protocol
used in the semi-quantitative PCR was the same to that used in the
qualitative PCR, except for the addition of 2.5 U of Taq DNA polymerase
and 1 µg of the clinical sample DNA. For the semi-quantitative PCR,
samples containing 80000, 8000, 800 and 80 plasmid particles were
tested simultaneously with the clinical samples. The PCR products were
Table 1
Primers used in the CMV qualitative, CMV semi-quantitative PCR and in the
nested-PCR
Primers Nucleotide sequence Genome annealing
site
gB1 5’GAAACGCGCGGCAATCGG 3’ 81874 to 81891
gB2 5’ TGGAACTGGAACGTTTGGC3’ 82158 to 82176
GBn1 5’GCGCCGTTGATCCACACACC 3’ 81960 to 81979
GBn2 5’TACGCTGCAGTTCACCCCAG 3’ 82055 to 82055
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subjected to electrophoresis in 2% agarose gel and the amplicons were
visualized by UV light and photographed with the Science 1D digital
came (Kodak, USA). The amplicon band densities were determined using
the DC120 Digital Access software (Kodak, USA).
 The CMV load of the clinical samples was determined by plotting
the amplicon band density value of each sample into a graphic including
samples containing 80000, 8000, 800 and 80 plasmid particles, as shown
in Fig. 1.
Statistical analysis: Personal and clinical data as well as laboratory
test results were confronted to results of the CMV qualitative and of the
semi-quantitative PCR tests by using the Chi-square and the Fisher’s
exact test (p < 0.05).
RESULTS
Qualitative PCR: Sixty three (26.5 %) of the 237 randomly selected
HIV infected individuals had CMV genome detected in the PBL.
Nineteen (8%) of the 237 randomly selected HIV infected individuals
had CMV genome detected in the plasma. Only 4 patients had CMV
genome detected in both leukocytes and plasma (Fig. 2). The positive
results were confirmed for all the clinical samples by nested PCR.
 Only one (10%) patient of the 10 individuals presenting clinical
manifestations suggestive of CMV disease had CMV genome detected
in the leukocytes by qualitative PCR. None of these patients had CMV
genome detected in plasma.
Semiquantitative PCR: CMV DNA load was determined in the 63
randomly selected HIV infected individuals having CMV genome
detected in PBL by qualitative PCR (Fig. 3). The semi-quantitative PCR
showed that in 10 cases (15.8%) the CMV loads ranged between 928 to
332 880 copies/µg DNA. The remaining 53 individuals had CMV load
under 800 viral copies/µg DNA, the sensitivity limit of the method.
 One patient from those presenting clinical manifestations suggestive
of CMV disease had CMV genome detected in the leukocytes by
qualitative PCR and showed a CMV load of 8 000 000 viral copies/µg
DNA.
Personal and clinical data of patients having CMV genome detected
by qualitative PCR: The average age of the 82 patients having CMV
genome detected by qualitative PCR was 34.2 years, the average CD4
lymphocyte count 279.96 cells/mm3; and the average HIV load 10,000
copies/ml of plasma. Seventy patients were using high active anti-
retroviral therapy. No significant association of patient age, gender, HIV
load, CD4 and CD8 leukocyte counts and infection stage with CMV
genome detection was observed. Likewise, none of the patients having
CMV genome detected by qualitative PCR presented clinical
manifestations associated to CMV disease and no association of CMV
Fig. 1 - Graphic of density values of amplicon bands obtained from 800, 8 000, 80 000,
800 000, 8 000 000 gB CMV plasmids in the semi-quantitative PCR.
Fig. 2 - Positivity of the CMV qualitative PCR in serum, buffy coat and in both samples in
the group of 237 HIV infected patients. The small pizza highlight 59 patients with positive
test only in the buffy coat, 15 patients with positive test only in the serum and 4 patients with
positive test in both, buffy coat and serum.
Fig. 3 - Electrophoresis in 2% agarose gel showing: in columns 12 to 17, amplicons with
296 bp of the plasmid titration (ten-fold dilutions; 17 = 8 X 106 plasmids; 16 = 8 X 105
plasmids; 15 = 8 X 104 plasmids; 14 = 8 X 103 plasmids; 13 = 8 X 102 plasmids, and 12 = 80
plasmids. The amplicon band is not observed in column 12 due to the low plasmid quantity
that is below the sensitivity of the test. Patient samples were run in columns 1 to 11, showing
amplicon bands in columns 3 (15 768 CMV copies/µg DNA); 7 (8 875 CMV copies/µg
DNA), and 9 (332 880 CMV copies DNA/µg). In columns 1, 2, 4, 6 and 10, are shown
amplicon bands with a lower density than the sensitivity of the test. In columns 5, 8 and 11,
amplicon bands cannot be observed.
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load with the use of anti-retroviral therapy and death evolution was
observed.
Personal and clinical data of patients having a determined CMV
load: Personal and clinical data of the patients having a determined CMV
load are shown in Table 2. These patients had an average of CD4
lymphocyte count of 384.9 cells/mm3 and HIV load average of 76,000
copies/ml of plasma. No significant association of patient age, gender,
HIV load, CD4 and CD8 leukocyte counts, and infection stage with CMV
load was observed. Likewise, none of these patients presented clinical
manifestations associated to CMV disease. No association of CMV load
with the use of anti-retroviral therapy was observed. A significant
association between deadliness rates and CMV load was observed (p <
0.005) in the patients. However, the death diagnosis of these cases,
nosocomial pneumonia and intestinal acute perforation, could not be
included as CMV disease clinical manifestations.
 In the group of individuals presenting clinical manifestations, the patient
presenting high CMV load (8 000 000 viral copies/µg DNA) also showed
the lowest CD4 lymphocyte count, 0.5 cells/mm3, and came to death.
DISCUSSION
A 95% prevalence of IgG antibodies to CMV in pregnant women of
Ribeirão Preto was reported by YAMAMOTO et al. in 199918. This high
prevalence of CMV infections in the adult population is probably also
observed in the HIV infected population. However, despite a high
incidence of CMV infections a great decrease of CMV disease it is
probably due to the raised use of HAART4,14,15,17. In our study, CD4
lymphocyte counts below 100 cells/mm3 were observed in a small number
of the HIV infected patients having CMV genome detected (12/82, 13%)
and only one of these cases was confirmed as having CMV disease. Our
data corroborate those reported by the other authors4,14,15,17.
PCR method is considered a valuable tool for diagnosis in virology
due to a high sensitivity that allows detection of very low amounts of
DNA in clinical samples. CMV genome can be easily detected by PCR
in PBL samples14. This method has been used in our laboratory for the
diagnosis of CMV infections, testing urine, blood of children and kidney
transplant recipients, with suitable performance1,18.
We presented a transversal study using the blood samples of 237
HIV infected patients. CMV DNA was detected in 34% of these cases
by qualitative PCR. Likewise, Marin in personal communication, using
the same PCR method detected CMV DNA in 27.3% of 37 kidney
transplant recipient patients in Ribeirão Preto. Our results show a higher
frequency of CMV infections when compared to those observed by the
other authors. PELLEGRIN et al. in 199914, found CMV genome in
19.8% of 58 HIV infected French patients.
Table 2
Clinical and laboratorial data of the 10 HIV infected patients that had a determined CMV load
Patient Age Gender HIV-load CD4 CD8 *Stage CMV load Opportunistic infections Evolution
Copies/ml cel/mm3 cel/mm3 CDC-93 Viral copies/g DNA Treatment
JCD 37 M 12 000 285 643 C-3 3311 Neuro-cryptococcosis Death
HAART**
MRLS 34 F 4 900 239 494 A-3 21837 None OI**** Stable
HAART
ERM 31 F 55 000 72 380 A-3 14278 None Stable
HAART
RB 34 M 260 000 281 996 C-3 31167 Retinitis Death
HAART
DL 45 M 1 800 269 1434 C-3 26866 Strongyloidiasis Stable
HAART
CCJ 33 M 6 700 887 1432 C-3 332880 None OI Stable
No treatment
VSF 33 M 200 000 628 1948 A-1 15,768 No treatment Death
MATA 19 M 73 000 522 627 A-1 9,918 No treatment Stable
AMTB 36 M 140 000 242 946 C-3 928 Histoplasmosis Stable
HAART
JPS 41 M 1 800 424 1391 A-3 8,875 HAART Stable
*Clinical classification; **HAART-Anti-retroviral therapy; ***ND-not done; **** OI-Opportunist infection.
Fig. 4 - Positivity of the CMV qualitative PCR tests in the buffy coat of the 237 HIV infected
patients, highlighting 10 cases having a determined CMV load and other 53 positive patients
whose CMV load was below to the sensitivity test.
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CMV genome was detected in the plasma of only 8% of our HIV
infected patients. This positive result rate is not higher than that reported
by PELLEGRIN et al.14 in the plasma of French HIV infected patients,
13%. The presence of CMV DNA in plasma shows that the virus is
replicating, despite the lower sensitivity of the test when using plasma
for CMV genome detection if compared to blood leukocytes. The
diagnosis of CMV replication in the blood is named active infection, it
is known as a high-risk condition for the development of CMV disease.
In the subgroup of 19 patients having CMV genome detected in plasma,
the virus was observed in the plasma but not in the PBL for 15 cases.
This intriguing fact could be a result of CMV replication in other sites
(mainly endothelial cells) rather than PBL11,14.
 CMV DNA was detected in PBL of 26.5% (63 patients) of the HIV
infected cases, showing higher sensitivity when compared to the CMV
detection in plasma. Blood leukocytes are known as traditional sites for
CMV replication10, and besides the amount of DNA in PBL is higher
than in plasma, even using ion change column to extract DNA from
plasma. Based on these results, PBL should be chosen as the most suitable
blood component for CMV genome detection.
 The sensitivity of the semi-quantitative PCR tested in the present
work was of 800 CMV copies/µg of DNA, which is probably adequate
for the diagnosis of CMV active infection and CMV disease.
 In the group of 237 HIV infected patients chosen randomly only 10
had CMV load determined with rates of 928 to 332 000 CMV copies/µg
DNA. Despite being active infection cases, CMV disease was not
observed during the follow-up of these 10 patients. We associated the
absence of CMV disease with the use of HAART in 70% of the studied
patients. Most of the patients having CMV genome detected, 53
individuals, showed a low CMV load, under 800 viral copies/µg DNA,
probably due to a partial control of the CMV replication by the immune
system, particularly in those patients using antiretroviral drugs.
 In the group of 10 individuals presenting clinical manifestations,
one patient had a severe form of CMV disease causing hepatitis, retinitis,
and lung infiltrates. This patient with a high CMV load, 8 000 000 viral
copies/µg DNA, also showed a very low CD4 lymphocyte count, 0.5
cells/mm3, and came to death, despite usual treatment to CMV7. The
diagnosis of CMV disease of this patient was also corroborated by the
presence of cytomegalic inclusions in hepatocytes. The absence of CMV
active infection in 90% of our patients presenting clinical manifestations
suggestive of CMV disease show clearly the low specificity of the clinical
suspicion only based on clinical manifestations and that those signals
and symptoms can also occur in other infections of AIDS patients.
 In short, qualitative PCR followed by confirmatory nested-PCR with
gB primers allowed the screening of CMV infections in HIV infected
patients. The CMV genome was detected in an expressive amount of
patients. However, qualitative PCR was not able to diagnose or to
discriminate CMV active infection or disease. The semi-quantitative PCR
was able to detect CMV load in 11 patients. Despite being active infection
cases, only 1 of these patients presented CMV disease. This patient
presented a very high CMV load and a severe form of disease. The
difficulty on finding CMV disease cases in the 247 HIV infected cases
is probably due to the use of HAART by these patients which increase
the number of CD4 cells and improves their cellular immune responses.
Further studies are necessary in order to confirm the usefulness of this
CMV semi-quantitative PCR in HIV infected patients.
RESUMO
Diagnóstico de infecção por CMV em pacientes infectados pelo
HIV utilizando PCR qualitativa e quantitativa
Uma alta incidência de infecção pelo citomegalovirus (CMV) é
observada no Brasil. Este vírus é responsável por significante morbi-
mortalidade entre pacientes infectados pelo vírus da imunodeficiência
humana (HIV). Neste estudo, mostramos a aplicação de uma PCR
quantitativa para determinar a carga de CMV nos leucócitos do sangue
periférico e no plasma de 247 pacientes infectados pelo HIV. As amostras
clínicas foram previamente testadas por uma PCR qualitativa e
confirmadas por uma nested-PCR para posteriormente serem
quantificados. Contagem de linfócitos T CD4, carga viral do HIV e
sintomas de doença citomegálica foram correlacionados com carga de
CMV. O genoma de CMV foi detectado nos leucócitos do sangue
periférico em 82 de um total de 237 (34%) pacientes, em 10 destes a
carga de CMV foi detectada variando de 928 a 332880 cópias virais/µg
de DNA. Nenhum destes 237 pacientes desenvolveu manifestação clínica
sugestiva de doença pelo citomegalovírus. Para outro grupo de 10
pacientes infectados pelo HIV e selecionados com base na suspeita de
doença pelo CMV, o genoma do CMV foi detectado em apenas um caso.
Este paciente apresentava alta carga de CMV (8 000 000 de cópias virais/
µg de DNA), desenvolvendo forma disseminada de doença pelo CMV o
que incluiu hepatite e retinite. Nossos resultados foram fortemente
influenciados pelo impacto da terapia antiretroviral que reduziu a
incidência da viremia por CMV, bem como a ocorrência de doença
citomegálica em pacientes infectados pelo HIV.
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